Investigational drug · Phase 2
Ivaltinostat
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Pancreatic Adenocarcinoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "Ivaltinostat"
First trial start
2022
Aug 15, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ivaltinostat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Pancreatic Adenocarcinoma
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Ivaltinostat" as an intervention, largest first.
- A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic AdenocarcinomaActive, not recruiting
CG Pharmaceuticals, IncIndustry
NCT05249101 · 70 participants (planned) · Start Aug 15, 2022 · Primary completion Jun 2026
Drug: Ivaltinostat; Capecitabine · For: Metastatic Pancreatic Adenocarcinoma
Sites: Scottsdale, Arizona; Newport Beach, California; San Francisco, California · 16 sites in all
Machaon Biotherapeutics, Inc.Industry
NCT05716919 · 32 participants · Start Mar 9, 2023 · Primary completion Dec 2023
Drug: Ivaltinostat · For: Hematologic Malignancy; Solid Tumor; Fibrosis
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Multiscale molecular modeling-directed ROS-responsive nanotherapy for dual-axis regulation of fibrotic and inflammatory signaling in alport nephropathy.
Choi HS, Sundaram A, Vasukutty A, et al. · J Nanobiotechnology 2026
- Pharmacokinetics, pharmacodynamics and safety of oral formulation (CG-750) of ivaltinostat, a histone deacetylase inhibitor, compared to IV formulation (CG-745).
Kim B, Huh KY, Yu KS, et al. · Br J Clin Pharmacol 2024
- A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma.
Jo JH, Jung DE, Lee HS, et al. · Int J Cancer 2022
Also in development for Metastatic Pancreatic Adenocarcinoma
- SetidegrasibASP3082Phase 32 trials
Astellas · Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- PepinemabPhase 21 trial
Vaccinex Inc. · Metastatic Pancreatic Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.